Bayer has acquired full rights to two drugs partnered with Loxo Oncology, on the same day that the biotech was taken over by Eli Lilly in an $8 billion deal. Bayer first partnered with Loxo on the ...

In BRUIN, LOXO-305 was tested in various types of NHL, including 61 patients with mantle cell lymphoma (MCL) and 19 with Waldenström's macroglobulinemia (WM) who had previously been treated with ...

Roche’s Itovebi joined the party late last year. Lilly’s attempt to follow its peers took a hit last year when it axed LOXO-783 after comparing clinical data on the molecule to its next ...